Market Closed -
Nasdaq
21:00:00 25/06/2024 BST
|
5-day change
|
1st Jan Change
|
4.71
USD
|
-7.47%
|
|
-17.66%
|
-1.09%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
1,473
|
2,314
|
1,070
|
321.6
|
323.4
|
352.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,842
|
2,292
|
858.3
|
248.3
|
323.4
|
352.4
|
352.4
|
352.4
|
P/E ratio
|
-0.45
x
|
-2.85
x
|
-0.62
x
|
-1.52
x
|
-3.9
x
|
-15.8
x
|
-152
x
|
15.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.28
x
|
9.43
x
|
4.83
x
|
1.84
x
|
1.2
x
|
1.17
x
|
1.01
x
|
0.87
x
|
EV / Revenue
|
5.28
x
|
9.43
x
|
4.83
x
|
1.84
x
|
1.2
x
|
1.17
x
|
1.01
x
|
0.87
x
|
EV / EBITDA
|
-7.17
x
|
-20.3
x
|
-21
x
|
-57.2
x
|
25.4
x
|
20.6
x
|
9.72
x
|
6.04
x
|
EV / FCF
|
-2.13
x
|
-8.78
x
|
-7.53
x
|
-2.52
x
|
-
|
-13.6
x
|
20.9
x
|
-
|
FCF Yield
|
-47%
|
-11.4%
|
-13.3%
|
-39.7%
|
-
|
-7.35%
|
4.78%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,741
|
19,798
|
21,477
|
34,213
|
54,539
|
54,549
|
-
|
-
|
Reference price
2 |
151.2
|
116.9
|
49.80
|
9.400
|
5.930
|
6.460
|
6.460
|
6.460
|
Announcement Date
|
22/09/20
|
27/09/21
|
20/09/22
|
14/06/23
|
20/06/24
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
278.9
|
245.5
|
221.3
|
175
|
270.3
|
302.4
|
349.8
|
405
|
EBITDA
1 |
-205.3
|
-114.1
|
-51.05
|
-5.625
|
12.75
|
17.12
|
36.24
|
58.37
|
EBIT
1 |
-491
|
-282.8
|
-231.4
|
-158.1
|
-46.45
|
-46.55
|
6.392
|
42.9
|
Operating Margin
|
-176.03%
|
-115.21%
|
-104.57%
|
-90.36%
|
-17.19%
|
-15.39%
|
1.83%
|
10.59%
|
Earnings before Tax (EBT)
1 |
-3,384
|
-699.8
|
-1,720
|
-221.5
|
-59.6
|
-3.004
|
9.348
|
-
|
Net income
1 |
-3,310
|
-695.1
|
-1,718
|
-199
|
-65.58
|
-19.56
|
-1.358
|
18.69
|
Net margin
|
-1,186.9%
|
-283.17%
|
-776%
|
-113.73%
|
-24.26%
|
-6.47%
|
-0.39%
|
4.61%
|
EPS
2 |
-339.4
|
-41.00
|
-79.90
|
-6.200
|
-1.520
|
-0.4100
|
-0.0425
|
0.4100
|
Free Cash Flow
1 |
-693
|
-263.7
|
-142.1
|
-127.8
|
-
|
-25.9
|
16.85
|
-
|
FCF margin
|
-248.46%
|
-107.41%
|
-64.18%
|
-73.03%
|
-
|
-8.56%
|
4.82%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
46.49%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/09/20
|
27/09/21
|
20/09/22
|
14/06/23
|
20/06/24
|
-
|
-
|
-
|
Fiscal Period: Maart |
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
50.43
|
50.22
|
49.26
|
61.68
|
61.68
|
64.03
|
75.11
|
63.42
|
64.42
|
67.41
|
77.57
|
70.01
|
72.78
|
78.61
|
EBITDA
1 |
-12.26
|
-12.85
|
-8.7
|
1.428
|
1.428
|
0.31
|
2.155
|
3.398
|
4.349
|
1.891
|
2.35
|
3.021
|
4.527
|
6.96
|
EBIT
|
-72.38
|
-63.9
|
-53.82
|
-71.6
|
-71.6
|
-32.68
|
-16.11
|
-11.05
|
-23.89
|
3.15
|
-
|
-
|
-
|
-
|
Operating Margin
|
-143.52%
|
-127.25%
|
-109.26%
|
-116.08%
|
-116.08%
|
-51.05%
|
-21.45%
|
-17.42%
|
-37.09%
|
4.67%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-1,012
|
-620.1
|
-63.86
|
-67.28
|
-67.28
|
-90.39
|
-22.11
|
0.384
|
-25.28
|
-14.04
|
-4.424
|
-0.5905
|
-7.188
|
6.615
|
Net income
1 |
-1,012
|
-618.8
|
-51.6
|
-65.39
|
-67.2
|
-82
|
-26.9
|
-0.523
|
-25.56
|
-21.12
|
-6.948
|
-7.881
|
-5.477
|
-2.07
|
Net margin
|
-2,006.93%
|
-1,232.28%
|
-104.75%
|
-106.02%
|
-108.95%
|
-128.07%
|
-35.81%
|
-0.82%
|
-39.68%
|
-31.34%
|
-8.96%
|
-11.26%
|
-7.53%
|
-2.63%
|
EPS
2 |
-47.20
|
-25.90
|
-1.700
|
-2.000
|
-2.000
|
-2.500
|
-0.8000
|
-
|
-0.5000
|
-0.4100
|
-0.1300
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/05/22
|
20/09/22
|
10/11/22
|
10/02/23
|
09/02/23
|
14/06/23
|
10/08/23
|
09/11/23
|
08/02/24
|
20/06/24
|
-
|
-
|
-
|
-
|
Fiscal Period: Maart |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
|
369
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
21.9
|
211
|
73.3
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.797
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-693
|
-264
|
-142
|
-128
|
-
|
-25.9
|
16.9
|
-
|
ROE (net income / shareholders' equity)
|
-11.7%
|
-12.4%
|
-11.6%
|
-
|
-
|
-0.8%
|
4.3%
|
9.8%
|
ROA (Net income/ Total Assets)
|
-9.21%
|
-9.65%
|
-8.46%
|
-
|
-
|
-0.4%
|
2.2%
|
5.1%
|
Assets
1 |
35,943
|
7,205
|
20,315
|
-
|
-
|
4,889
|
-61.72
|
366.4
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-34.60
|
-12.50
|
-5.110
|
-
|
-
|
0.2200
|
0.7800
|
1.190
|
Capex
1 |
355
|
53.1
|
32.2
|
12.1
|
-
|
10.5
|
11.6
|
12.8
|
Capex / Sales
|
127.29%
|
21.62%
|
14.55%
|
6.93%
|
-
|
3.48%
|
3.33%
|
3.16%
|
Announcement Date
|
22/09/20
|
27/09/21
|
20/09/22
|
14/06/23
|
20/06/24
|
-
|
-
|
-
|
Last Close Price
6.46
CAD Average target price
9.619
CAD Spread / Average Target +48.90% Consensus |
1st Jan change
|
Capi.
|
---|
| +29.76% | 5.68B | | -32.34% | 3.59B | | -2.23% | 3.12B | | -25.26% | 2.62B | | -10.88% | 2.3B | | +40.09% | 1.88B | | +40.90% | 1.45B | | -15.16% | 1.39B | | +42.86% | 1.37B |
Alternative Medicine
|